Market Research Report
Market Access Impact: HIV (EU5) 2018
|Published by||FirstWord||Product code||497069|
Delivery time: 1-2 business days
Please contact us using the inquiry form for pricing information.
|Market Access Impact: HIV (EU5) 2018|
|Published: March 1, 2018||Content info:||
Market barriers affect just over a tenth of HIV prescriptions. Is your brand losing out?
In EU5 markets, where market barriers affect just over one in 10 HIV prescriptions, no single brand has a significant lead over other brands. Market share for all players is up for grabs! Find out what's driving share gains, and what your brand can do to level the playing field in Market Access Impact: HIV (EU5) .
Based on a survey of 150 infectious disease specialists from the EU5 markets (France, Germany, Italy, Spain, UK), the report covers 11 major therapies from Gilead, ViiV, Merck Sharp & Dohme, BMS and Janssen Cilag. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Insight into 11 Major HIV Drugs
Exploring Market Access Barriers
Market Access Impact: HIV (EU5) explores key issues affecting HIV drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 150 infectious disease specialists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world. All respondents have:
We conducted the survey between March 5-12, 2018.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.